Article in Human gene therapy, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.9field-weighted citation impact, top 13% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
4 citing papers in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
7 authors at 2 institutions in 1 country.
Jessica D UmañaDivision of Chemical Biology and Medicinal Chemistry,Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0003-1114-7051
Sara R WassermanDivision of Chemical Biology and Medicinal Chemistry,Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Liujiang SongGene Therapy Center, School of Medicine, University of North Carolina, Chapel Hill, North Carolina, USA.
Arushi A GoelDivision of Chemical Biology and Medicinal Chemistry,Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.
Xufen YuMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Jian JinMount Sinai Center for Therapeutics Discovery, Departments of Pharmacological Sciences and Oncological Sciences, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
Nathaniel A HathawayDivision of Chemical Biology and Medicinal Chemistry,Center for Integrative Chemical Biology and Drug Discovery, UNC Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0002-9807-0167
University of North Carolina at Chapel Hill · USIcahn School of Medicine at Mount Sinai · US
Funding
MECHANISM OF HP1-MEDIATED HETEROCHROMATIN ASSEMBLY AND DURABILITY IN LIVE CELLSR01GM118653 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HATHAWAY, NATHANIEL A. · 2017 to 2021
$1.7M
ILLUMINATION OF CHROMATIN REGULATION VIA CHEMICAL CONTROLLED PROXIMITYR35GM148365 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Nathaniel A. Hathaway · 2023 to 2026
$1.7M
UNC Chemical Biology Interface Training ProgramT32GM135122 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Jeffrey Aube · 2021 to 2026
$1.6M
Computational and experimental insights into the structure and dynamics of heterochromatinR01GM132299 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HATHAWAY, NATHANIEL A., KIREEV, DMITRI · 2020 to 2023
$1.2M
Enhancement Training for the Next Generation of Translational Ph.D. ScientistsT32GM122741 · NIGMS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI WOLBERG, ALISA S., YEH, JEN JEN · 2018 to 2022
$898k
An AVANCE NEO 400 MHz NMR Spectrometer for Chemical Biology and Drug DiscoveryS10OD028504 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ZHOU, MING-MING · 2020 to 2020
$599k
An AVANCE NEO 600 MHz NMR Spectrometer System for Structural and Chemical BiologyS10OD025132 · OD · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · PI ZHOU, MING-MING · 2019 to 2019
$535k
Chemically regulating AAV transgene expression with endogenous gene activatorsR21AI164214 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI HATHAWAY, NATHANIEL A., HIRSCH, MATTHEW LOUIS · 2022 to 2023
$446k
Novel platform for optimizing AAV transgene expression to improve efficacy of ocular gene therapiesR41EY033603 · NEI · EPIGENOS BIOSCIENCE, INC. · PI HIRSCH, MATTHEW LOUIS · 2022 to 2022
Adeno-associated virus (AAV) is a powerful gene therapy vector that has been used in several FDA-approved therapies as well as in multiple clinical trials. This vector has high therapeutic versatility with the ability to deliver genetic payloads to a variety of human tissue types, yet there is currently a lack of transgene expression control once the virus is administered. There are also times when transgene expression is too low for the desired therapeutic outcome, necessitating high viral dose administration resulting in possible immunological complications. Herein, we validate a chemically controllable AAV transgene expression technology
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Chemical Epigenetic Regulation of Adeno-Associated Virus Delivered Transgenes. · full record | OpenQuestion